Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
The deal was announced on Thursday, and it was signed with MSD Animal Health, known as Merck Animal Health.
This is second agreement, as MSD Animal Health and Valneva had already signed a commercial license agreement in 2009 allowing MSD Animal health to develop and commercialize EB66-based vaccines for an undisclosed indication.
Thomas Lingelbach, CEO, and Franck Grimaud, Deputy CEO of Valneva, said: “We are extremely pleased to extend our collaboration with such a global healthcare leader as MSD Animal Health. We look forward to MSD Animal Health developing new innovative veterinarian vaccines using our EB66 cell line.”
Financial terms of the agreements were not disclosed.